Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2024
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.12%
|
-
|
|
Apr 02
2024
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.65%
|
-
|
|
Apr 02
2024
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.51%
|
-
|
|
Apr 02
2024
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
120,400
+15.92%
|
-
|
|
Apr 02
2024
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+12.47%
|
-
|
|
Apr 02
2024
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+13.35%
|
-
|
|
Apr 02
2024
|
Jay S Stout Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+26.19%
|
-
|
|
Apr 02
2024
|
Michael Geffner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+27.51%
|
-
|
|
Apr 02
2024
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+12.77%
|
-
|
|
Apr 02
2024
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+10.62%
|
-
|
|
Apr 02
2024
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,534
+12.82%
|
-
|
|
Feb 22
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,134
-0.7%
|
$76,824
$36.15 P/Share
|
|
Feb 22
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,930
-0.91%
|
$105,480
$36.15 P/Share
|
|
Feb 22
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,146
-0.52%
|
$77,256
$36.15 P/Share
|
|
Feb 22
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,221
-0.67%
|
$79,956
$36.15 P/Share
|
|
Feb 22
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,454
-1.42%
|
$484,344
$36.15 P/Share
|
|
Jan 26
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,101
-5.06%
|
$383,838
$38.18 P/Share
|
|
Jan 26
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,027
-0.49%
|
$115,026
$38.18 P/Share
|
|
Jan 18
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
424
-0.13%
|
$17,384
$41.03 P/Share
|
|
Jan 11
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,515
-0.54%
|
$147,630
$42.04 P/Share
|
|
Jan 05
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,297
-0.32%
|
$49,286
$38.59 P/Share
|
|
Jan 05
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,824
-0.4%
|
$145,312
$38.59 P/Share
|
|
Dec 01
2023
|
Andrew J. Fromkin Director |
SELL
Open market or private sale
|
Direct |
12,350
-4.25%
|
$481,650
$39.68 P/Share
|
|
Dec 01
2023
|
George V Migausky Director |
SELL
Open market or private sale
|
Direct |
12,700
-3.58%
|
$495,300
$39.69 P/Share
|
|
Dec 01
2023
|
Atul Pande Director |
SELL
Open market or private sale
|
Direct |
12,350
-4.51%
|
$481,650
$39.69 P/Share
|
|
Nov 22
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,217
-0.84%
|
$535,161
$33.14 P/Share
|
|
Nov 22
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,055
-0.61%
|
$133,815
$33.14 P/Share
|
|
Nov 22
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,265
-0.48%
|
$107,745
$33.14 P/Share
|
|
Nov 22
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,265
-0.39%
|
$107,745
$33.14 P/Share
|
|
Nov 22
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,252
-0.52%
|
$107,316
$33.14 P/Share
|
|
Oct 25
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,107
-1.31%
|
$139,638
$34.66 P/Share
|
|
Oct 19
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
530
-0.16%
|
$19,080
$36.8 P/Share
|
|
Oct 10
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,557
-1.36%
|
$164,052
$36.92 P/Share
|
|
Oct 05
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,735
-0.21%
|
$60,725
$35.97 P/Share
|
|
Oct 05
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,239
-0.27%
|
$183,365
$35.97 P/Share
|
|
Oct 02
2023
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
1,526,316
+1.88%
|
$58,000,008
$38.0 P/Share
|
|
Oct 02
2023
|
Roivant Sciences Ltd. |
BUY
Grant, award, or other acquisition
|
Direct |
4,473,684
+5.41%
|
$169,999,992
$38.0 P/Share
|
|
Aug 30
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
56,774
-2.78%
|
$1,249,028
$22.22 P/Share
|
|
Aug 24
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,286
-1.88%
|
$245,720
$20.59 P/Share
|
|
Aug 24
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
12,333
-1.44%
|
$246,660
$20.59 P/Share
|
|
Aug 24
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,386
-2.06%
|
$287,720
$20.59 P/Share
|
|
Aug 24
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,333
-1.76%
|
$246,660
$20.59 P/Share
|
|
Aug 14
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
103,058
-4.61%
|
$2,164,218
$21.69 P/Share
|
|
Aug 07
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
101,339
-8.23%
|
$2,128,119
$21.73 P/Share
|
|
Jul 26
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,917
-1.18%
|
$82,257
$21.63 P/Share
|
|
Jul 19
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,725
-0.77%
|
$65,400
$24.94 P/Share
|
|
Jul 19
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
426
-0.12%
|
$10,224
$24.94 P/Share
|
|
Jul 12
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,470
-0.34%
|
$27,930
$19.73 P/Share
|
|
Jul 12
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,233
-0.26%
|
$61,427
$19.73 P/Share
|
|
Apr 25
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
509
-0.15%
|
$8,144
$16.29 P/Share
|